CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity

Clinical Cancer Research

Volumn 13, Issue 10, 2007, Pages 2970-2976

  Zandvliet, Anthe S ^a   Huitema, Alwin D R ^a   Copalu, William ^c   Yamada, Yasuhide ^d   Tamura, Tomohide ^d   Beijnen, Jos H ^a,e   Schellens, Jan H M ^b,e  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c EISAI CO LTD   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; INDISULAM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; ENZYME POLYMORPHISM; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUTROPENIA; PANCREAS CARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOME, HUMAN; HUMANS; LIVER; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NEOPLASMS; POLYMORPHISM, GENETIC; RISK; SULFONAMIDES;

EID: 34249803213     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2978     Document Type: Article

References (36)

1. Fukuoka K, Usuda J, Iwamoto Y, et al. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non - small cell lung cancer cells. Invest New Drugs 2001;19:219-27.
2. van Kesteren C, Beijnen JH, Schellens JHM. E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anticancer Drugs 2002;13:989-97.
3. Haddad RI, Weinstein LJ, Wieczorek TJ, et al. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res 2004;10:4680-7.
4. Raftopoulos H, Escudier B, Renshaw G, et al.: A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with inoperable and/or metastatic renal cell carcinoma (RCC) [abstract]. J Clin Oncol American Society of Clinical Oncology Annual Meeting Proceedings (Post-Meeting Edition) 2004;22:414s.
5. Smyth JF, Aamdal S, Awada A, et al. Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol 2005;16:158-61.
6. Fumoleau P, Viens P, Cottu PH, et al. A multi center phase II study of E7070, a chloroindolyl-sulfonamide anticancer agent in anthracycline and taxane pre treated breast cancer [abstract]. 26th San Antonio Breast Cancer Symposium 2003.
7. Talbot DC, Norbury C, Slade M, et al. A phase II and pharmacodynamic study of E7070 in patients with non - small cell lung cancer (NSCLC) who have failed platinum-based chemotherapy [abstract]. Proc Am Soc Clin Oncol 2002;21:327a.
8. Mainwaring PN, Van Cutsem E, Van Laethem JL, et al. A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy [abstract]. Proc Am Soc Clin Oncol 2002;21:153a.
9. Raymond E, ten Bokkel Huinink WW, Taieb J, et al. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 2002;20:3508-21.
10. Punt CJA, Fumoleau P, van de Walle B, Faber MN, Ravic M, Campone M. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann Oncol 2001;12:1289-93.
11. Terret C, Zanetta S, Roche H, et al. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur J Cancer 2003;39:1097-104.
12. Dittrich C, Dumez H, Calvert H, et al. Phase I and pharmacokinetic study of E7070, a chloroindolylsulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res 2003;9:5195-204.
13. Raymond E, Fumoleau P, Roche H, et al. Combined results of 4 phase I and pharmacokinetic studies of E7070, a novel chloroindoly-sulphonamide inhibiting the activation of cdk2 and cyclin E [abstract]. Clin Cancer Res 2000;6:4529s.
14. Yamada Y, Yamamoto N, Shimoyama T, et al. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Sci 2005;96:721-8.
15. van Kesteren C, Mathôt RAA, Raymond E, et al. Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol 2002;20:4065-73.
16. Zandvliet AS, Schellens JHM, Copalu W, Beijnen JH, Huitema ADR. A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. J Pharmacokinet Pharmacodyn 2006;33:543-70.
17. van Kesteren C, Zandvliet AS, Karlsson MO, et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 2005;23:225-34.
18. van den Bongard HJGD, Pluim D, Rosing H, et al. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anticancer Drugs 2002;13:807-14.
19. Beumer JH, Hillebrand MJX, Pluim D, et al. Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients. Invest New Drugs 2005;23:317-30.
20. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999;57:465-80.
21. Beumer JH, Rosing H, Hillebrand MJX, et al. Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzene disulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2004;18:2839-48.
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Bioanalytical Method Validation. 2001.
23. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
24. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
25. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002;54:1257-70.
26. Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003;56:653-7.
27. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to Phenytoin. Pharmacogenetics 2001;11:803-8.
28. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999;9:539-49.
29. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64.
30. Ferguson RJ, De Morais SM, Benhamou S, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998;284:356-61.
31. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997;281:604-9.
32. Ibeanu GC, Goldstein JA, Meyer U, et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998;286:1490-5.
33. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996;333:447-58.
34. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
35. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001;60:382-7.
36. Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004;38:1702-6.